Bottom Line Three independent 2026 surveys agree on the direction, even though they report different numbers: employer coverage of GLP-1 medications for weight loss is retrenching, not expanding, as the drugs’ cost collides with the size of the eligible population. Several large, recognizable employers have dropped or are dropping coverage this year. For patients whose
Bottom Line A large real-world study published in January 2026 found that people with type 2 diabetes on tirzepatide had a lower rate of newly diagnosed dementia over two years than people on semaglutide or on SGLT2 inhibitors, and that semaglutide also outperformed SGLT2 inhibitors. The differences are real and statistically significant, but this is
Employers are dropping GLP-1 weight-loss coverage Three 2026 surveys point the same way. A Business Group on Health survey found 60% of large employers now cover GLP-1s for weight loss, down from 72% in 2025, with Cigna and PwC already out and PepsiCo and Starbucks following in October. Employers Health says about 65% of its
Bottom Line GLP-1 medications are being prescribed to young children with obesity far more than they were even a few years ago, and clinical trials are now testing them in children as young as 6. But approval and evidence have not kept pace with use: no GLP-1 medication is currently FDA-approved for obesity treatment in
